Strong age but weak sex effects in eye movement performance in the general adult population: Evidence from the Rhineland Study

Assessing physiological changes that occur with healthy ageing is prerequisite for understanding pathophysiological age-related changes. Eye movements are studied as biomarkers for pathological changes because they are altered in patients with neurodegenerative disorders. However, there is a lack of data from large samples assessing age-related physiological changes and sex differences in oculomotor performance. Thus, we assessed and quantified cross-sectional relations of age and sex with oculomotor performance in the general population. We report results from the first 4,000 participants (aged 30-95 years) of the Rhineland Study, a communitybased prospective cohort study in Bonn, Germany. Participants completed fixation, smooth pursuit, prosaccade and antisaccade tasks. We quantified associations of age and sex with oculomotor outcomes using multivariable linear regression models. Performance in 12 out of 18 oculomotor measures declined with increasing age. No differences between age groups were observed in five antisaccade outcomes (amplitudeadjusted and unadjusted peak velocity, amplitude gain, spatial error and percentage of corrected errors) and for blink rate during fixation. Small sex differences occurred in smooth pursuit velocity gain (men have higher gain) and blink rate during fixation (men blink less). We conclude that performance declines with age in two thirds of oculomotor outcomes but that there was no evidence of sex differences in eye movement performance except for two outcomes. Since the percentage of corrected antisaccade errors was not associated with age but is known to be affected by pathological cognitive decline, it represents a promising candidate preclinical biomarker of neurodegeneration.

Automated summary

Assessing the physiological changes related to healthy ageing is essential for understanding pathological age-related changes. Eye movements are studied as biomarkers for neurodegenerative disorders, with most oculomotor performance declining with age. However, there is minimal evidence of sex differences in eye movement performance, except for a few outcomes.